A Randomized, Open-Label, Cross-Over, Dose-Ranging Study to Assess the Effect of Vecam 40/300 and Vecam 20/300 Administered at Bedtime Compared to Omeprazole 20 mg Administered Before Breakfast on Gastric pH.

Trial Profile

A Randomized, Open-Label, Cross-Over, Dose-Ranging Study to Assess the Effect of Vecam 40/300 and Vecam 20/300 Administered at Bedtime Compared to Omeprazole 20 mg Administered Before Breakfast on Gastric pH.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2012

At a glance

  • Drugs VECAM (Primary) ; Omeprazole
  • Indications Gastric ulcer; Gastro-oesophageal reflux; Heartburn; Helicobacter infections; Peptic ulcer
  • Focus Pharmacodynamics
  • Sponsors Vecta
  • Most Recent Events

    • 01 May 2012 Results published in Neurogastroenterology and Motility.
    • 05 May 2010 Results have been presented at Digestive Disease Week (DDW) 2010.
    • 28 Jan 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top